Efficacy and Safety of Tolvaptan in Patients More Than 90 Years Old With Acute Heart Failure.

Yusuke SatoHiroyasu UzuiMoe MukaiYuichiro ShiomiKanae HasegawaHiroyuki IkedaNaoto TamaYoshitomo FukuokaTetsuji MorishitaKentaro IshidaKenichi KasenoShinsuke MiyazakiAkira NakanoHiroshi Tada

Published in: Journal of cardiovascular pharmacology and therapeutics (2019)

The efficacy and safety of tolvaptan in AHF patients aged more than 90 years were comparable to those of <90 years old. Tolvaptan provides a complementary therapeutic option for AHF patients aged more than 90 years.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes
atrial fibrillation
patient reported